Stock 1672 ASCLETIS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Market Closed - Hong Kong S.E.
Other stock markets
 01:39:00 03/05/2024 pm IST 		5-day change 1st Jan Change
1.42 HKD +1.43% Intraday chart for Ascletis Pharma Inc. +4.41% -2.74%
03/04 Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus MT
03/04 Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis
Ascletis Pharma Gets Nod to Trial Acne Drug
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Presents Data on Studies for Liver Treatments at US Liver Disease Meet
Ascletis Pharma Publishes Results of Gannex's Fatty Liver Medication
Ascletis Pharma Presents Data in Germany from Phase 2 Study on Anti-Acne Drug
Ascletis Pharma Finds Envafolimab Safe to Use in Study
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
Ascletis Enrolls 120 Patients in Phase 3 Clinical Trial for Combination Treatment for Glioblastoma; Shares Fall 6%
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
Ascletis' H1 Attributable Loss Narrows as Revenue Jumps
Ascletis Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Ascletis Pharma's HIV Drug Clinical Data Presented at Australia Medical Conference
Ascletis Unit Completes Patient Enrollment for Phase 2 Trial for Biliary Cholangitis Drug; Shares Rise 8%
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1672 Stock
  4. News Ascletis Pharma Inc.
  5. Other languages